MilliporeSigma Invests $20 Million in New Switzerland Laboratory

August 3, 2020
Pharmaceutical Technology Editors

In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter 08-05-2020, Volume 15, Issue 8

The investment will allow for the expansion of analytical R&D efforts and will support the company’s reference materials business.

MilliporeSigma plans to build a new, $20-million laboratory facility in Buchs, Switzerland, to support its rapidly growing reference materials business, the company announced in a July 15, 2020 press release. The company anticipates that about two dozen jobs will be created with this expansion.

The three-story, 12,000-ft2 Buchs building is scheduled to be done by December 2021, and the move to the facility is planned for early 2022. The facility will include laboratory and office space aimed at fostering a collaborative environment. The new facility will offer a more efficient working environment for current and future employees in R&D, analytical production, and quality control. The laboratory area can be adapted to new requirements in the future, including increased site capacity.

"Researchers in testing labs around the world use MilliporeSigma’s reference materials every day to help generate accurate, reliable analytical results in pharmaceutical, environmental, and food and beverage analysis,” said Jean-Charles Wirth, head of Applied Solutions at MilliporeSigma, in the company press release. “This new laboratory will allow us to continue to drive innovation in diagnostics and testing and expand our research and development of analytical standards.”

Source: MilliporeSigma